R- 2- (3- N- (2- benzo(1,4)dioxanylmethyl)- amino- 1- propyl)- 3(2H)- pyridazinone hydrochloride

The combined alpha1- and postsynaptically selective alpha2-blocker GYKI-16084 significantly improved the AUA symptom scores and increased Q(max) in patients with BPH, without inducing any adverse reaction, orthostatic changes or erectile dysfunction

Also Known As:

GYKI-16084

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridazines: 11
    - R-2-(3-N-(2-benzo(1,4)dioxanylmethyl)-amino-1-propyl)-3(2H)-pyridazinone hydrochloride: 1

Experts

1.	Horváth, Katalin: 1 article (06/2006)
2.	Romics, Imre: 1 article (06/2006)
3.	Varga, Attila: 1 article (06/2006)
4.	Walter, György: 1 article (06/2006)

Related Diseases

1.	Erectile Dysfunction 06/01/2006 - "The combined alpha1- and postsynaptically selective alpha2-blocker GYKI-16084 significantly improved the AUA symptom scores and increased Q(max) in patients with BPH, without inducing any adverse reaction, orthostatic changes or erectile dysfunction."
2.	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 06/01/2006 - "To assess the clinical efficacy and safety of the combined alpha1- and postsynaptic alpha2-blocker GYKI-16084 compared to placebo during a 28-day active treatment of patients with benign prostatic hyperplasia (BPH). "